CanadaBis Capital (CANB) AI Stock Analysis

• Market Cap: C$5.53M
• Dividend Yield: N/A
• Average Volume (3M): 56.47K
• Price to Earnings (P/E): 80.0
• Beta (1Y): -0.39
• Revenue Growth: -8.84%
• EPS Growth: -96.82%
• Country: CA
• Employees: N/A
• Sector: Financial
• Sector Strength: 82
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 138,256,380
• 10 Day Avg. Volume: 98,665
• 30 Day Avg. Volume: 56,466
• PEG Ratio: 0.01
• Price to Book (P/B): 5.49
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 8.71
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: C$0.00 ▼(-100.00%Downside)

The overall stock score reflects mixed financial performance and bearish technical indicators. While there are positive corporate events supporting future growth, the high valuation and negative cash flows present significant risks. Strategic initiatives and financial improvements are crucial for enhancing the company's market position.

CanadaBis Capital Business Overview & Revenue Model

Company Description

CanadaBis Capital, Inc. (CANB) is a Canadian company operating within the cannabis sector. The company is focused on the production and distribution of cannabis products, leveraging its vertically integrated operations to supply both medical and recreational markets. CanadaBis Capital aims to deliver high-quality cannabis products while maintaining a strong commitment to sustainability and innovation.

How the Company Makes Money

CanadaBis Capital, Inc. generates revenue primarily through the cultivation, production, and sale of cannabis products. The company operates a vertically integrated business model, which means it controls the entire supply chain from cultivation to distribution. This allows CanadaBis to produce various cannabis products, including dried flower, oils, and edibles, for both medical and recreational consumers. Revenue streams include direct sales to consumers, wholesale agreements with dispensaries and retailers, and possibly partnerships with other companies in the cannabis industry to expand its market reach. Additionally, the company's focus on innovation and quality helps it maintain a competitive edge, potentially leading to higher sales and market share.

CanadaBis Capital Financial Statement Overview

Summary

CanadaBis Capital, Inc. is experiencing financial challenges, particularly in terms of cash flow management and profitability. While strengths are seen in gross profit margins and a reasonable equity ratio, the declining revenue, low net profit margin, and negative cash flows indicate a need for strategic adjustments for improved financial health.

Income Statement

CanadaBis Capital, Inc. shows a mixed performance on the income statement. The gross profit margin for TTM is approximately 47.5%, indicating efficient production cost management relative to revenue. However, the net profit margin is low at 1.1%, reflecting challenges in controlling operating expenses or other costs. Revenue has decreased over the past year, with the most recent TTM revenue at $17.89 million compared to $22.22 million two years prior, showing a negative growth trajectory. EBIT and EBITDA margins are also relatively low, signaling limited operating profitability.

Balance Sheet

The balance sheet presents a moderately stable financial structure. The debt-to-equity ratio for TTM stands at approximately 0.71, which is somewhat high and suggests a reliance on debt financing. The return on equity (ROE) is low at 2.4%, indicating limited efficiency in generating profits from shareholders' equity. However, the equity ratio is at a solid 33%, suggesting a reasonable proportion of assets financed by equity, providing a buffer against liabilities.

Cash Flow

The cash flow statement reveals challenges in liquidity management. The operating cash flow to net income ratio is negative, as the company reported a negative operating cash flow of -$176,696 for the TTM, indicating difficulties in converting sales to actual cash. Free cash flow is also negative and has decreased over time, from $4.57 million two years ago to -$480,187 in the latest TTM, highlighting cash flow constraints and potential issues with sustaining operations without external funding.

Breakdown	TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	17.89M	17.95M	22.22M	11.67M	6.87M	4.43M
Gross Profit	8.50M	8.82M	11.78M	5.57M	2.52M	1.16M
EBITDA	1.64M	2.09M	5.68M	1.63M	-1.81M	-4.43M
Net Income	201.75K	600.28K	4.44M	608.33K	-2.68M	-5.39M
Balance Sheet
Total Assets	25.55M	24.55M	22.96M	15.48M	13.28M	12.52M
Cash, Cash Equivalents and Short-Term Investments	1.33M	1.68M	3.23M	144.88K	849.50K	167.00K
Total Debt	5.95M	6.44M	7.31M	7.82M	8.44M	6.06M
Total Liabilities	17.04M	16.45M	15.62M	12.84M	11.46M	9.09M
Stockholders Equity	8.42M	8.00M	7.25M	2.54M	1.73M	3.34M
Cash Flow
Free Cash Flow	-480.19K	-594.48K	4.57M	-292.54K	-1.96M	-8.58M
Operating Cash Flow	-176.70K	-256.31K	5.55M	-82.77K	-1.81M	-3.62M
Investing Cash Flow	-303.49K	-328.33K	-965.82K	-209.77K	122.77K	-2.39M
Financing Cash Flow	-586.44K	-962.02K	-1.50M	-412.09K	2.37M	5.85M

CanadaBis Capital Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CANB, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.05, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.82 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CANB.

CanadaBis Capital Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	67 Neutral	$17.07B	11.91	9.69%	3.75%	11.66%	-9.47%
CANB	51 Neutral	C$5.53M	80.00	0.83%	―	-8.84%	-96.82%
IMCC	51 Neutral	$9.13M	―	-63.75%	―	9.34%	69.69%
PCLO	24 Underperform	$8.45M	―	184.66%	―	125.70%	47.09%

CanadaBis Capital Corporate Events

CanadaBis Capital Achieves Positive Q3 2025 Financial Results Amid Market Challenges

CanadaBis Capital has reported its financial results for Q3 2025, achieving a positive adjusted EBITDA of $440,665 despite a challenging market environment. The company recorded gross sales of $5.5 million and a 6% increase in gross earnings over previous periods. Strategic cost management and product innovation, including the launch of diamond and Keef-coated pre-rolls, have been pivotal in maintaining operational efficiency. Additionally, CanadaBis has reduced its short-term debt by $2.5 million and plans to launch innovative vape hardware later this year, positioning itself for future growth in the cannabis sector.

CanadaBis Capital Ends Arrangement Agreement with Simply Solventless

CanadaBis Capital Inc. has terminated its Arrangement Agreement with Simply Solventless Concentrates Ltd., which was intended for SSC to acquire all issued and outstanding shares of CanadaBis. The decision to terminate was due to a ‘Material Adverse Change’ concerning SSC, deemed in the best interest of CanadaBis shareholders and stakeholders. Consequently, all voting and support agreements related to the transaction have been automatically terminated, and a special meeting of CanadaBis shareholders has been canceled.

CanadaBis Capital Completes $4 Million Financing to Boost Cannabis Growth

CanadaBis Capital Inc. has successfully closed the final tranche of its brokered private placement, raising a total of $4,035,000 through the issuance of unsecured convertible debentures. This financing move, facilitated by Research Capital Corporation, is expected to bolster CanadaBis’s financial position and support its growth strategies in the cannabis industry, particularly in the concentrates segment. The debentures, which mature in 2029, offer a conversion option into common shares, providing flexibility for investors and potentially enhancing shareholder value.